Alpha 2.0
Login Register
» Articles » PMID: 28750150

Are Checkpoint Inhibitors a Valuable Option for Metastatic or Unresectable Vulvar and Vaginal Melanomas?

Overview
Journal J Eur Acad Dermatol Venereol
Specialty Infectious Diseases
Date 2017 Jul 28
PMID 28750150
Citations 9
Authors
G Quereux
S Wylomanski
R Bouquin
M Saint-Jean
L Peuvrel
A C Knol
M Hanf
B Dreno
Affiliations
Soon will be listed here.
Citing Articles

Clinical features of vulvar and vaginal malignant melanomas and the effects of immune checkpoint inhibitors in Japanese patients: a single-center, retrospective cohort study.

Horisaki K, Yoshikawa S, Omata W, Tsutsumida A, Kiyohara Y Melanoma Res. 2024; 35(1):67-74.

PMID: 39630629 PMC: 11670917. DOI: 10.1097/CMR.0000000000001012.

Genitourinary melanoma: An overview for the clinician.

DePalo D, Elleson K, Carr M, Spiess P, Zager J Asian J Urol. 2022; 9(4):407-422.

PMID: 36381597 PMC: 9643129. DOI: 10.1016/j.ajur.2022.01.003.

Near complete remission of a locally advanced giant melanoma of the vulva following hypo-fractionated radiotherapy and immune checkpoint inhibitors: A case report.

Chen S, Deng X, Xie C, Dong Q, Yang H Oncol Lett. 2022; 24(6):458.

PMID: 36380876 PMC: 9650599. DOI: 10.3892/ol.2022.13578.

Anorectal and Genital Mucosal Melanoma: Diagnostic Challenges, Current Knowledge and Therapeutic Opportunities of Rare Melanomas.

Ottaviano M, Giunta E, Marandino L, Tortora M, Attademo L, Bosso D Biomedicines. 2022; 10(1).

PMID: 35052829 PMC: 8773579. DOI: 10.3390/biomedicines10010150.

Immuno-Oncology for Gynecologic Malignancies.

How J, Patel A, Jazaeri A Adv Exp Med Biol. 2022; 1342:193-232.

PMID: 34972966 DOI: 10.1007/978-3-030-79308-1_6.